Active Ingredient(s): Givosiran Sodium
FDA Approved: * November 20, 2019
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Givlaari Overview

Givosiran, sold under the brand name Givlaari, is for the treatment of adults with acute hepatic porphyria,[1] a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood).[2][3] Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, an important enzyme in the production of heme.[4] The U.S. Foo...

Read more Givlaari Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Givlaari Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Givosiran Sodium
  • Solution: 189mg/ml (189mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Givlaari: (1 result)

Sorted by National Drug Code
  • 71336-1001 Givlaari 189 mg/ml Subcutaneous Injection, Solution by Alnylam Pharmaceuticals, Inc.

Other drugs which contain Givosiran Sodium or a similar ingredient: (1 result)